Articles

Select Category

All News

Articles

Briefings & Statements

All Presidential Actions

Executive Orders

Nominations & Appointments

Presidential Memoranda

Proclamations

Fact Sheets

Remarks

President Donald J. Trump is determined to make the American pharmaceutical and biotechnology industries great again — both as a matter of national security and to unleash unprecedented prosperity for American workers.

Gilead Sciences became the latest industry leader to announce a massive new investment in its U.S. operations with an $11 billion boost to its planned U.S.-based spending.

The company joins a host of others in expanding their domestic footprint to align with President Trump’s vision:

New Jersey-based Johnson & Johnson announced a $55 billion investment in manufacturing, research and development, and technology.
Roche, a Swiss drug and diagnostics company, announced a $50 billion investment in its U.S.-based manufacturing and research and development.
New Jersey-based Bristol Myers Squibb announced a $40 billion investment in research, development, technology, and manufacturing.
Indiana-based Eli Lilly and Company announced a $27 billion investment to more than double its domestic manufacturing capacity.
Novartis, a Swiss drugmaker, announced a $23 billion investment to build or expand ten manufacturing facilities across the U.S.
Illinois-based AbbVie announced a $10 billion investment over the next ten years to support volume growth and add four new manufacturing plants to its network.
New Jersey-based Merck & Co. announced it will invest a total of $9 billion over the next several years after opening a new $1 billion North Carolina manufacturing facility — including a new state-of-the-art biologics manufacturing plant in Delaware.
- Merck Animal Health announced an $895 million investment to expand their manufacturing operation in Kansas.
New York-based Regeneron Pharmaceuticals announced a $3 billion agreement with FUJIFILM Diosynth Biotechnologies to produce drugs at its North Carolina facility.
California-based Amgen announced a $900 million investment in its Ohio-based manufacturing operation.
Illinois-based Abbott Laboratories announced a $500 million investment in its Illinois and Texas facilities.